Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Aldeyra Therapeutics ( (ALDX) ).
On May 1, 2026, Aldeyra Therapeutics released an updated corporate overview detailing standardized treatment estimates and confidence intervals for the primary endpoints of all proposed commercial dosing regimen efficacy trials of reproxalap in dry eye disease. The presentation also summarized Aldeyra’s interpretations of U.S. Food & Drug Administration positions on those endpoints alongside the company’s own views, providing investors and stakeholders more clarity on the data submitted in the New Drug Application.
The update underscores the strategic importance of reproxalap within Aldeyra’s broader RASP-modulation platform, which spans ophthalmic, dermatologic, metabolic, hepatic, and CNS indications. By combining detailed efficacy analyses with disclosure of its financial runway to 2028, Aldeyra positioned itself as a well-capitalized immunology-focused biotech with multiple late- and early-stage programs that could shape its future regulatory and commercial trajectory.
The most recent analyst rating on (ALDX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Aldeyra Therapeutics stock, see the ALDX Stock Forecast page.
Spark’s Take on ALDX Stock
According to Spark, TipRanks’ AI Analyst, ALDX is a Neutral.
The score is pressured primarily by weak financial performance (no revenue, ongoing losses, and elevated cash burn risk) and bearish technicals (sharp downtrend with negative momentum). Corporate events are mixed—debt repayment is a positive, but the second FDA rejection is a significant negative—and valuation support is limited given negative earnings and no dividend.
To see Spark’s full report on ALDX stock, click here.
More about Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for immune-mediated diseases. Its pipeline centers on modulating reactive aldehyde species (RASP) and includes lead candidate reproxalap for dry eye disease and allergic conjunctivitis, as well as ADX-2191, ADX-248, and ADX-246 for a range of retinal, dermatologic, metabolic, and neuroinflammatory conditions.
The company pursues a systems-based pharmacology approach that aims to modulate protein systems rather than single protein targets, seeking broader efficacy with potentially reduced toxicity. Aldeyra reports that as of December 31, 2026, it held $70 million in cash, cash equivalents, and marketable securities, which it believes will fund operations into 2028, supporting continued early- and late-stage development of its immunology pipeline.
Average Trading Volume: 3,039,910
Technical Sentiment Signal: Sell
Current Market Cap: $91.69M
Learn more about ALDX stock on TipRanks’ Stock Analysis page.